Q/C Technologies, Inc.QCLS

NasdaqHealthcareIn Vitro & In Vivo Diagnostic Substances
Price (close)
$1.02
Market cap
—
P/E
—
Revenue (TTM)
—
Net income
-$16.6M
Dividend yield
—
1-year total return
-78.3%
Net margin
—
Revenue growth
—
Debt / equity
—

What Q/C Technologies, Inc. does.

platforms based on well-defined biological targets, including Isomyosamine and Supera-CBD. More recently, the Company has shifted

its business strategy to focus on energy-efficient blockchain and cryptocurrency infrastructure through quantum-class laser-based

Company’s core strategy is centered on leveraging an exclusive global licensing agreement with LightSolver Ltd. (“LightSolver”)

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue——————
Net income-$9.5M-$29.9M-$15.2M-$4.0M-$23.4M-$11.6M
Free cash flow—————-$10.8M

More on QCLS.

Figures from Q/C Technologies, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.